Therma Bright to Spin Off Consumer Product Portfolio to Create Two Publicly Traded Companies
Therma Bright to Spin Off Consumer Product Portfolio to Create Two Publicly Traded Companies
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner in advanced diagnostic and medical device technologies, has completed its announced strategic review, and has set the course to spin-off the Company's Consumer Product Portfolio into its own separate publicly traded company. This move is aimed at strengthening Therma Bright's strategic and operational focus, capitalizing on growth opportunities, and unlocking shareholder value.
安大略省多倫多--(資訊 CORP - 2024年11月18日) - Therma Bright Inc.(TSXV:THRM)(OTCQB:TBRIF),一家領先的先進診斷和醫療器械技術開發及投資合作伙伴,已完成其宣佈的戰略審查,並決定將公司的消費產品組合拆分成一個獨立的上市公司。此舉旨在增強Therma Bright的戰略和運營重點,抓住增長機會,並釋放股東價值。
Both companies are expected to maintain a strong strategic relationship, preserving a key value proposition for shareholders. It is anticipated that the spin-off will be completed during the first half of 2025.
預計這兩家公司將保持強有力的戰略關係,爲股東保留關鍵價值主張。預計拆分將在2025年上半年完成。
The spin-off transaction will require shareholder approval. In order to preserve cash and avoid the double costs of holding two shareholder meetings within months of each other, Therma Bright has obtained the necessary regulatory approvals to defer this year's AGM for up to six months, such that it must be held no later than June 30, 2025. Consequently, the Company has cancelled the AGM which it had originally scheduled for December 31, 2024. Therma Bright will provide shareholders with updates on the status of this transaction in the coming months as material information becomes available.
拆分交易將需要股東批准。爲了節省現金並避免在幾個月內召開兩次股東會議的雙重成本,Therma Bright已獲得必要的監管批准,將今年的股東大會推遲至最多六個月,確保不遲於2025年6月30日召開。因此,公司已取消原定於2024年12月31日舉行的股東大會。Therma Bright將在未來幾個月內向股東提供有關此交易狀態的更新,隨着重要信息的發佈。
Spin-Off Overview:
拆分概述:
Therma Bright's board and management team have determined that as part of the Company's strategic business review of its portfolio, as previously announced on March 21, 2024, that a spin-off of its Consumer Product Portfolio provides the best path to enhance the company's value, as it will create two (2) publicly traded companies, each with its own market potential. This will allow for more focus around each company's product development, sales and marketing, operation and distribution, as well as enhance shareholder value.
Therma Bright的董事會和管理團隊已判斷,在公司之前於2024年3月21日宣佈的戰略業務審查中,拆分其消費產品組合提供了提升公司價值的最佳路徑,因爲這將創建兩個(2)各自具有市場潛力的上市公司。這將使每家公司在產品開發、銷售和市場推廣、運營和分銷方面有更多的關注,同時提升股東價值。
"Our management and board have determined that the spin-off of our consumer products will generate greater focus for each business's success, while enhancing shareholder value." expressed Rob Fia, Chairman and CEO of Therma Bright. "We have great confidence that now is the ideal time for this spin-off given the current market conditions, and the expected growth of the consumer medical device industry, particularly in the North America. "
Therma Bright的董事長兼首席執行官Rob Fia表示:「我們的管理層和董事會決定,拆分我們的消費產品將爲每個業務的成功產生更大的關注,同時提升股東價值。」他表示:「考慮到目前的市場條件,以及消費者醫療器械行業在北美的預期增長,我們對現在是拆分的理想時機充滿信心。」
Transaction details around the spin-off will be forth coming, as Therma Bright shareholders are expected to receive a pro-rata distribution of shares of the new Company's stock. The spin-off is subject to confirmation by the Company's legal and tax advisors to determine the most advantageous structure for both Therma Bright and its shareholders with respect to tax purposes.
關於分拆的交易細節將會公佈,因爲Therma Bright的股東預計將按比例獲得新公司的股票分配。分拆需公司法律和稅務顧問確認,以判斷對Therma Bright及其股東在稅務方面最有利的結構。
Furthermore, Therma Bright is dedicated to optimizing strong capital allocation strategies for each company, in line with their respective long-term goals. Further details pertaining to the transaction, such as each companies' respective capital structures and capital requirements, governance, and other elements, will be announced at the appropriate time.
此外,Therma Bright致力於爲每家公司優化強有力的資本配置策略,以符合它們各自的長期目標。與交易相關的進一步細節,例如每家公司的資本結構、資本需求、治理及其他因素,將在適當的時候公佈。
Although THRM expects to complete the spin-off within the aforementioned time frame, this transaction is subject to all customary conditions including the final approval of the Therma Bright Board of Directors, receipt of a tax opinion, the filing and effectiveness of disclosure statements, and obtaining all necessary regulatory approvals.
雖然THRm預計將在上述時間框架內完成分拆,但此次交易須符合所有常規條件,包括Therma Bright董事會的最終批准、收到稅務意見、提交併生效的披露聲明,以及獲得所有必要的監管批准。
Consumer Product Portfolio:
消費產品組合:
Subsequent to the spin-off, the Company's consumer medical devices will include TheroZapTM insect bite therapy device, InterceptCS cold sore prevention system, Benepod hot and cold pain relief device and AcuVidTM Covid-19 rapid antigen test technology. Per Research and Markets, "The Pain Management Devices Market is valued at USD 7.94 billion in 2024 and is anticipated to grow at a CAGR of 4.8 %, during the forecast period to 2035." According to Fortune Business Insights, "The global skincare market size was valued at USD 109.71 billion in 2023 and is projected to grow from USD 115.65 billion in 2024 to USD 194.05 billion by 2032, exhibiting a CAGR of 6.68% during the forecast period."
分拆後,公司的消費醫療設備將包括TheroZapTm昆蟲叮咬治療設備、InterceptCS冷瘡預防系統、Benepod冷熱痛症緩解設備和AcuVidTm Covid-19快速抗原檢測技術。根據Research and Markets,"疼痛管理設備市場在2024年的估值爲79.4億美元,預計在2035年的預測期間內以4.8%的年複合增長率增長。" 根據Fortune Business Insights,"全球護膚市場在2023年的規模估值爲1097.1億美元,預計在2024年將增長到1156.5億美元,到2032年預計達到1940.5億美元,展示出在預測期間內6.68%的年複合增長率。"
"By creating two focused, agile companies that can pursue tailored sales and marketing strategies aligned with specific long-term growth goals, we believe that both companies will experience rapid growth in their own right," stated Rob Fia. "As separate public companies with a commercial relationship, we are confident in delivering a superior outcome and will provide further updates on the spin-off progress in the coming months."
Rob Fia表示:"通過創建兩個專注、靈活的公司,以追求與特定長期增長目標相一致的量身定製的銷售和營銷策略,我們相信這兩家公司都將在各自的領域快速增長。" "作爲擁有商業關係的獨立上市公司,我們有信心提供卓越的結果,並將在未來幾個月內提供有關分拆進展的進一步更新。"
Sources: and
來源: 和
About Therma Bright Inc.:
關於Therma Bright Inc.:
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright是一家開發和合作夥伴,擁有一系列領先的專有診斷和醫療設備技術,專注於爲消費和醫療專業人士提供質量卓越、創新的解決方案,以應對當今一些最重要的醫療和健康護理挑戰。Therma Bright Inc.在(TSXV:THRM)(OTCQB:TBRIF)(FSE:JNX)交易。訪問:。
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Therma Bright Inc.
首席執行官Rob Fia
rfia@thermabright.com
Follow us on:
Twitter
關注我們:
推特
FORWARD-LOOKING STATEMENTS
前瞻性聲明
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as the spin out of the Company's consumer product portfolio as a separate public company as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
本新聞稿中的某些陳述構成「前瞻性」陳述。這些陳述與未來事件以及相關信息有關,例如本新聞稿中所述的將公司的消費產品組合作爲獨立上市公司的分拆。所有這些陳述都涉及大量已知和未知的風險、不確定性以及可能導致實際結果與這些前瞻性陳述所表達或暗示的結果產生差異的其他因素。前瞻性陳述涉及重大風險和不確定性,不能被解讀爲對未來業績或結果的保證,並且並不一定準確地指示這些結果是否會實現。由於多個因素和風險,實際結果可能與預期結果存在顯著差異。儘管本新聞稿中包含的前瞻性陳述是基於管理層在本新聞稿日期所認爲的合理假設,但公司不能向投資者保證實際結果將與這些前瞻性陳述一致。該新聞稿中包含的前瞻性陳述是截至本日期作出的,公司 disclaim 任何更新或修訂前瞻性陳述的意圖或義務,無論是因爲新信息、未來事件還是其他原因,除非根據適用的證券法規要求。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
無論是TSX創業公司交易所還是其監管服務提供者(按TSX創業公司交易所政策中的定義)均不對本新聞稿的充足性或準確性承擔責任。